- In September 25, 2023, NervGen Pharma Corporation, a clinical-stage biotech company focused on treatments for nervous system damage, announced that the first participant had been dosed in their landmark Phase 1b/2a placebo-controlled clinical trial for NVG-291, their lead compound for spinal cord injury (SCI)
- In August 2023, Kaneka Corporation, an international chemical manufacturer based in Japan, initiated a Phase I/II clinical trial for KA-301, a treatment for acute spinal cord injury derived from human amnion-based mesenchymal stem cells. The cell preparations for this trial were developed through technology supported by Japan’s Science and Technology Agency (JST) under the NexTEP program
- In July 2023, NeuroSolv Therapeutics, based in Belfast, Northern Ireland, and Baltimore, U.S., partnered with AscellaHealth LLC, a global healthcare and specialty pharmacy solutions company. The collaboration aims to expand NeuroSolv’s clinical trial development program and expedite regulatory approval processes, with the goal of accelerating the market launch of their product, Perineline
- In June 2022, Amneal Pharmaceuticals, Inc. announced the commercial launch of LYVISPAH, an FDA-approved baclofen oral granules product (available in 5, 10, and 20 mg doses) designed to treat spasticity associated with multiple sclerosis and other spinal cord disorders
- In August 2021, Novartis AG announced that the FDA had lifted the partial clinical trial hold, originally imposed in October 2019, allowing the OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients to resume
- In July 2021, Mitsubishi Tanabe Pharma Corporation, a global pharmaceutical company, received fast track designation from the U.S. FDA for MT-3921, a treatment under development for spinal cord injury
